BerandaFGEN • NASDAQ
add
FibroGen Inc
Tutup sebelumnya
$8,90
Rentang hari
$8,60 - $9,19
Rentang tahun
$4,85 - $21,88
Kapitalisasi pasar
34,79 jt USD
Volume Rata-Rata
39,54 rb
Rasio P/E
0,16
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,08 jt | 774,80% |
Biaya operasional | 5,30 jt | -43,44% |
Penghasilan bersih | 200,64 jt | 1.274,41% |
Margin laba bersih | 18,65 rb | 234,25% |
Penghasilan per saham | 49,61 | 13.491,78% |
EBITDA | -5,18 jt | 81,77% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 117,98 jt | -9,94% |
Total aset | 137,01 jt | -48,18% |
Total liabilitas | 119,53 jt | -74,36% |
Total ekuitas | 17,48 jt | — |
Saham yang beredar | 4,05 jt | — |
Harga terhadap nilai buku | -2,11 | — |
Tingkat pengembalian aset | -8,52% | — |
Tingkat pengembalian modal | 52,71% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | 200,64 jt | 1.274,41% |
Kas dari operasi | -1,85 jt | 77,95% |
Kas dari investasi | 87,16 jt | 11.444,37% |
Kas dari pembiayaan | -85,92 jt | -67.551,18% |
Perubahan kas bersih | -1,87 jt | 80,78% |
Arus kas bebas | 72,84 jt | 1.077,84% |
Tentang
FibroGen, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2025, FibroGen was mainly reduced to a single early-stage oncology drug candidate. Wikipedia
Didirikan
1 Jan 1993
Kantor pusat
Situs
Karyawan
225
